Dr. Esther Cynn is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes genetics, cardiometabolic diseases, human nutrition, cellular and molecular biology. Esther applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Esther completed her doctorate degree at Columbia University. Her dissertation focused on understanding the function and mechanism of a macrophage-specific human long noncoding RNA, in the context of cardiovascular disease.
Dr. Esther Cynn is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Her background includes genetics, cardiometabolic diseases, human nutrition, cellular and molecular biology. Esther applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Esther completed her doctorate degree at Columbia University. Her dissertation focused on understanding the function and mechanism of a macrophage-specific human long noncoding RNA, in the context of cardiovascular disease.
- Ph.D., Nutritional and Metabolic Biology, Columbia University, 2022
- M.S., Human Nutrition, Columbia University, 2015
- B.S., Double Major in Chemistry and Biological Sciences, Cornell University, 2014
- U.S. Patent and Trademark Office
- Ph.D., Nutritional and Metabolic Biology, Columbia University, 2022
- M.S., Human Nutrition, Columbia University, 2015
- B.S., Double Major in Chemistry and Biological Sciences, Cornell University, 2014
- U.S. Patent and Trademark Office
Select Publications
- Co-author with T Cao, O’Reilly ME, et al., “Cis-regulated expression of Non-conserved LincRNAs Associates with Cardiometabolic Related Traits,” J Hum Genet, May 2022
- Co-author with AS Foulkes, C Selvaggi, et al., “Nonconserved Long Intergenic Noncoding RNAs Associate with Complex Cardiometabolic Disease Traits,” Arterioscler Thromb Vasc Biol, January 2021
Select Publications
- Co-author with T Cao, O’Reilly ME, et al., “Cis-regulated expression of Non-conserved LincRNAs Associates with Cardiometabolic Related Traits,” J Hum Genet, May 2022
- Co-author with AS Foulkes, C Selvaggi, et al., “Nonconserved Long Intergenic Noncoding RNAs Associate with Complex Cardiometabolic Disease Traits,” Arterioscler Thromb Vasc Biol, January 2021
The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.
For more information please see Prime Medicine’s press release.
- Privacy Policy
- Terms of Use
- Accessibility